Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 2Carcinoma, Renal Cell 2Neoplasms 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 131Cyclophosphamide 74fludarabine phosphate 51Whole-Body Irradiation 38Peripheral Blood Stem Cell Transplantation 36Mycophenolic Acid 36Tacrolimus 32Etoposide 28Busulfan 28Melphalan 24Lenalidomide 23Prednisone 22Filgrastim 22Cyclosporine 22Bortezomib 22Antilymphocyte Serum 21Vincristine 19Methotrexate 19obinutuzumab 17Bendamustine Hydrochloride 16fludarabine 15Doxorubicin 15Radiotherapy 14ibrutinib 13Dexamethasone 13Cytarabine 13Cord Blood Stem Cell Transplantation 13Carmustine 13pembrolizumab 12idelalisib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Follicular × Interferons × Clear all
NCT00577993 2020-11-16

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

M.D. Anderson Cancer Center

Phase 3 Completed
210 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡